Session 145 - 12th CROI

Home

Session 145 Poster Abstracts
Abacavir Hypersensitivity and Injection Site Reactions
Wednesday, 1:30 - 3:30 pm
Hall B

834	Abacavir Stimulates Hsp70 Redistribution in Antigen-presenting Cells of Patients with Hypersensitivity: Association with Type-I Alcohol Dehydrogenase Activity A Martin^1,5, C Almeida^1,5, D Nolan^1,5, P Cameron², I James^1,5, T Purcell³, J McCluskey³, E Phillips⁴, and Simon Mallal*^1,5 ¹Ctr for Clin Immunology and Biomed Statistics, Perth, Australia; ²Royal Perth Hosp, Australia; ³Univ of Melbourne, Victoria, Australia; ⁴British Columbia Ctr for Excellence in HIV/AIDS, Univ of British Columbia, Vancouver, Canada; and ⁵Murdoch Univ, Perth, Australia
835	Increased Rate and Severity of Abacavir-associated Hypersensitivity Reaction in Randomized Controlled Clinical Trials Andrea James* and R Johann-Liang FDA, Rockville, MD, USA
836	Once-daily Administration of Abacavir Is not a Clinical Risk Factor for Suspected Hypersensitivity Reactions in Clinical Trials, and Rash Alone Is not Sufficient to Diagnose the Reaction C Brothers, A Cutrell, H Zhao, M Edwards, J Fleming, T Scott, and Jaime Hernandez* GlaxoSmithKline, Research Triangle Park, NC, USA
837	Injection Site Reactions, Injection Difficulties, and Interventions in Enfurvitide Pivotal Clinical Trials: Focus on Subject Tolerability Neville Gibbs*, M Baylor, and R Johann-Liang FDA, Rockville, MD, USA
838	An Analysis of the Correlation between the Severity of Injection Site Reactions and the Amount of Subcutaneous Fat in the Alliance Cohort David Cooper and On behalf of the Alliance Investigator Group Univ of New South Wales, Sydney, Australia